Literature DB >> 18220511

Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms.

Frank M Longo1, Tao Yang, Juliet K Knowles, Youmei Xie, Laura A Moore, Stephen M Massa.   

Abstract

A number of factors limit the therapeutic application of neurotrophin proteins, such as nerve growth factor (NGF) and brain-derived growth factor (BDNF), for Alzheimer's and other neurodegenerative diseases. These factors include unfavorable pharmacological properties typical of proteins and the pleiotropic effects mediated by protein-ligand interactions with p75(NTR), Trk, and sortilin neurotrophin receptors. Targeted modulation of p75(NTR) provides a strategy for preventing degeneration without promoting TrkA-mediated deleterious effects, and targeted activation of TrkB might achieve more favorable neurotrophic effects than those achieved by concomitant activation of p75(NTR) and TrkB. The discovery of small molecules functioning as ligands at specific neurotrophin receptors has made possible for the first time approaches for modulating selected components of neurotrophin signaling processes for the purpose of modulating underlying Alzheimer's disease mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220511     DOI: 10.2174/156720507783018316

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  44 in total

1.  Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.

Authors:  Melissa J Alldred; Karen E Duff; Stephen D Ginsberg
Journal:  Neurobiol Dis       Date:  2011-11-07       Impact factor: 5.996

Review 2.  Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.

Authors:  Dimitrios Kapogiannis; Mark P Mattson
Journal:  Lancet Neurol       Date:  2010-12-10       Impact factor: 44.182

Review 3.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

4.  Novel p75 neurotrophin receptor ligand stabilizes neuronal calcium, preserves mitochondrial movement and protects against HIV associated neuropathogenesis.

Authors:  Rick B Meeker; Winona Poulton; Gillian Clary; Michael Schriver; Frank M Longo
Journal:  Exp Neurol       Date:  2015-09-28       Impact factor: 5.330

Review 5.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

Review 6.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

Review 7.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

Review 8.  Potential therapeutic uses of BDNF in neurological and psychiatric disorders.

Authors:  Alan H Nagahara; Mark H Tuszynski
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

Review 9.  Brain-derived neurotrophic factor in neurodegenerative diseases.

Authors:  Chiara Zuccato; Elena Cattaneo
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

10.  The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo.

Authors:  Juliet K Knowles; Jayakumar Rajadas; Thuy-Vi V Nguyen; Tao Yang; Melburne C LeMieux; Lilith Vander Griend; Chihiro Ishikawa; Stephen M Massa; Tony Wyss-Coray; Frank M Longo
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.